AI Article Synopsis
- Pancreatic cancer is highly aggressive and resistant to treatments, creating a need for new therapeutic options, particularly from plant-based sources.
- Researchers analyzed extracts from specific plants (Achillea millefolium and Calendula officinalis from the Asteraceae family, and Melissa officinalis and Origanum majorana from the Lamiaceae family) using advanced extraction methods to find effective treatments against pancreatic cancer cells.
- Results indicated that extracts from the Asteraceae family were more effective at killing cancer cells and inhibiting their growth than those from the Lamiaceae family, with the Supercritical CO2 extraction method proving to be the most efficient; the extracts from Yarrow and Marigold also enhanced the effects of a common chemotherapy drug
Article Abstract
Background: Pancreatic cancer is one of the most aggressive and mortal cancers. Although several drugs have been proposed for its treatment, it remains resistant and new alternatives are needed. In this context, plants and their derivatives constitute a relevant source of bioactive components which might efficiently inhibit tumor cell progression.
Methods: In this study, we have analyzed the potential anti-carcinogenic effect of different Asteraceae (Achillea millefolium and Calendula officinalis) and Lamiaceae (Melissa officinalis and Origanum majorana) plant extracts obtained by different green technologies (Supercritical CO Extraction -SFE- and Ultrasonic Assisted Extraction -UAE-) to identify efficient plant extracts against human pancreatic cancer cells that could constitute the basis of novel treatment approaches.
Results: Asteraceae extracts showed better results as antitumoral agents than Lamiaceae by inducing cytotoxicity and inhibiting cell transformation, and SFE extracts were most efficient than UAE extracts. In addition, SFE derived plant extracts from Achillea millefolium and Calendula officinalis displayed synergism with the chemotherapeutic 5-Fluororacil.
Conclusion: These results show how Yarrow and Marigold SFE-derived extracts can inhibit pancreatic cancer cell growth, and could be proposed for a comprehensive study to determine the molecular mechanisms involved in their bioactivity with the final aim to propose them as potential adjuvants in pancreatic cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142333 | PMC |
| http://dx.doi.org/10.1186/s12906-018-2322-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical performance of endoscopic ultrasound-guided tissue acquisition for perivascular soft-tissue cuffing suspected to be extravascular migratory metastases of pancreatic or bile duct cancer (with video).
Dig Endosc
December 2024
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Objectives: This study aimed to investigate the diagnostic performance and safety of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for perivascular soft-tissue cuffing (PSTC).
Methods: This single-center, retrospective study evaluated patients in whom EUS-TA was performed for PSTC in pancreatic or bile duct cancer lesions between October 2017 and March 2024. PSTC was defined as a perivascular soft-tissue area contiguous with nearby blood vessels from the suspected primary tumor.
Re: Simulating the healthcare workforce impact and capacity for pancreatic cancer care in Victoria: a model-based analysis.
ANZ J Surg
December 2024
Department of General Surgical Specialities, Royal Melbourne Hospital, Melbourne, Australia.
Unveiling the Masquerade: Early Gastric Cancer Mimicking Advanced Disease with Ectopic Pancreas Intrusion.
Ann Ital Chir
December 2024
Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy; General and Oncologic Surgery, Department of Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy.
Gastric cancer is a significant health concern worldwide, and its diagnosis and management are of paramount importance. Ectopic pancreas (EP) refers to an embryological abnormality where healthy pancreatic tissue develops without anatomical, vascular, or neural communication with the normal pancreas. We report the case of a patient whose initial endoscopic evaluation suggested early gastric cancer, but computed tomography scan (CT scan) and endoscopic ultrasound (EUS) indicated a locally advanced tumor.
View Article and Find Full Text PDFCase report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents.
Front Oncol
December 2024
Department of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extending into the IVC/RA, treated at our center.
View Article and Find Full Text PDFPrognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis.
Front Oncol
December 2024
Department of Gastroenterology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Background: The significance of the systemic inflammation response index (SIRI) in predicting the prognosis of patients with pancreatic cancer (PC) has been extensively explored; however, findings remain controversial. As such, this meta-analysis was performed to more precisely determine the utility of the SIRI in predicting PC prognosis.
Methods: A comprehensive literature search of the PubMed, Web of Science, Embase, and Cochrane Library databases for relevant studies, published up to June 25, 2024, was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!